This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cervical cancer	PC4 and SFRS1-interacting protein (PSIP1; LEDGF; p75; LEDGF/p75)	<p>Studies in cell culture and patient samples suggest inhibiting <i>LEDGF</i> expression could help treat HPV⁺ cervical cancers. In human HPV⁺ cervical cancer cells, siRNA against <i>LEDGF</i> increased sensitivity to genotoxic therapies, including radiation and camptothecin, compared with control siRNA. In human cervix biopsies, <i>LEDGF</i> expression was higher in HPV⁺ lesions than in normal samples. Next steps could include developing <i>LEDGF</i> inhibitors.</p> <p>SciBX 7(15); doi:10.1038/scibx.2014.428 Published online April 17, 2014</p>	Patent and licensing status unavailable	<p>Leitz, J. <i>et al. PLoS Pathog.</i>; published online March 6, 2014; doi:10.1371/journal.ppat.1003957 Contact: Felix Hoppe-Seyler, German Cancer Research Center, Heidelberg, Germany e-mail: hoppe-seyler@dkfz.de Contact: Karin Hoppe-Seyler, same affiliation as above e-mail: k.hoppe-seyler@dkfz.de</p>